Anvisa bans irregular insulin and tirzepatide sales in Brazil

Brazil’s National Health Surveillance Agency (Anvisa) has prohibited the sale and use of all insulin batches produced by Costa Mar Comércio Licitatório. The decision follows an inspection in Petrópolis that revealed the company was distributing insulin glargine without the required operating authorization and was not functioning at its registered address.

Additionally, Anvisa has banned the sale of various unregistered peptides, including a brand of tirzepatide sold via a specific website. Because these substances lack official registration, they are prohibited from being manufactured, distributed, advertised, or used by any individuals or legal entities.